Olanzapine and Fuoxetine vs Aripiprazole — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Atypical Antipsychotic

Olanzapine and Fuoxetine

Brand: Olanzapine and Fluoxetine

First FDA approval: 2012-11-26

Atypical Antipsychotic

Aripiprazole

Brand: ABILIFY

First FDA approval: 2002-11-15

Lowest NADACAcquisition cost floor across all NDCs

$3.76Per unit

$0.098Per unit

Average NADACAcross all dosage forms and strengths

$5.48Up to $7.48

$62.47Up to $2859.97

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

22108 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

$1.45BFull year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

6.2M1.3M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

$233Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

10Minimal friction

1127Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

372Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only

Yes22 manufacturers